A new drug called Spinraza (generic name: nusinersen) treats a rare disease, spinal muscular atrophy, that is the leading cause of genetic death in infants. It could be a blockbuster for makers Biogen and Ionis.
A new drug called Spinraza (generic name: nusinersen) treats a rare disease, spinal muscular atrophy, that is the leading cause of genetic death in infants. It could be a blockbuster for makers Biogen and Ionis.
Share this Article
Comment on this Article
Recommended
Please to comment